🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

207 results for “Smith” Clear

  1. Rotarix™

    GlaxoSmithKline

    Infections, Rotavirus

    phase 2 mab completed

    1 trial

  2. SB497115

    GlaxoSmithKline

    Purpura, Thrombocytopaenic, Idiopathic

    phase 2 small molecule completed

    1 trial

  3. SB497115

    GlaxoSmithKline

    Thrombocytopaenia

    phase 2 small molecule completed

    1 trial

  4. SERETIDE Rotacaps

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  5. Sodium Chloride Intravenous Infusion (0.9% w/v), BP, Benlysta 400 mg powder for concentrate for solution for infusion.

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  6. Solabegron

    GlaxoSmithKline

    Overactive Bladder

    phase 2 small molecule completed

    1 trial

  7. Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets

    GlaxoSmithKline

    Neoplasms

    phase 2 small molecule active

    1 trial

  8. albiglutide

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 2 mab completed

    1 trial

  9. dabrafenib

    GlaxoSmithKline

    Solid Tumours

    phase 2 small molecule completed

    1 trial

  10. meningococcal ACWY (vaccine)

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 mab completed

    1 trial

  11. pazopanib (GW786034)

    GlaxoSmithKline

    Neoplasms, Uterine Cervix

    phase 2 small molecule completed

    1 trial

  12. pazopanib (GW786034) 400 mg

    GlaxoSmithKline

    Neoplasms, Breast

    phase 2 small molecule completed

    1 trial

  13. sterile saline solution (0.9% w/v solution of NaCl in water).

    GlaxoSmithKline

    Urinary Tract Infections

    phase 2 small molecule active

    1 trial

  14. 50mg Ezogabine/retigabine

    GlaxoSmithKline

    Epilepsy

    phase 1 small molecule completed

    1 trial

  15. A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  16. A Phase 1 study of GSK5764227 in participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  17. A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  18. A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function

    GlaxoSmithKline

    Relapsed or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  19. A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Renal Function

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  20. A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese and Japanese Participants, and Participants with Interstitial Lung Disease Associated with Connective Tissue Disease (CTD-ILD)

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  21. A phase 1 study of GSK2857916 + Standard of Care (SOC) in first line multiple myeloma patients (DREAMM-9)

    GlaxoSmithKline

    Multiple Myeloma

    phase 1 other active

    1 trial

  22. A study for GSK3862995B in healthy participants and participants with Chronic Obstructive Pulmonary Disease

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 1 other active

    1 trial

  23. A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults.

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 1 other active

    1 trial

  24. A study to compare the pharmacokinetics of salbutamol administered via metered dose inhalers containing propellants HFA-152a (test) or HFA-134a (reference) in healthy participants aged 18 to 55 inclusive.

    GlaxoSmithKline

    Healthy volunteers

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources